Skip to main content

30.06.2017 | Comorbidities of Heart Failure (C Angermann and F Edelmann, Section Editors) | Ausgabe 4/2017 Open Access

Current Heart Failure Reports 4/2017

Inflammation – Cause or Consequence of Heart Failure or Both?

Current Heart Failure Reports > Ausgabe 4/2017
Sophie Van Linthout, Carsten Tschöpe
Wichtige Hinweise
This article is part of the Topical Collection on Comorbidities of Heart Failure


Purpose of Review

With the intention to summarize the currently available evidence on the pathophysiological relevance of inflammation in heart failure, this review addresses the question whether inflammation is a cause or consequence of heart failure, or both.

Recent Findings

This review discusses the diversity (sterile, para-inflammation, chronic inflammation) and sources of inflammation and gives an overview of how inflammation (local versus systemic) can trigger heart failure. On the other hand, the review is outlined how heart failure-associated wall stress and signals released by stressed, malfunctioning, or dead cells (DAMPs: e.g., mitochondrial DNA, ATP, S100A8, matricellular proteins) induce cardiac sterile inflammation and how heart failure provokes inflammation in various peripheral tissues in a direct (inflammatory) and indirect (hemodynamic) manner. The crosstalk between the heart and peripheral organs (bone marrow, spleen, gut, adipose tissue) is outlined and the importance of neurohormonal mechanisms including the renin angiotensin aldosteron system and the ß-adrenergic nervous system in inflammation and heart failure is discussed.


Inflammation and heart failure are strongly interconnected and mutually reinforce each other. This indicates the difficulty to counteract inflammation and heart failure once this chronic vicious circle has started and points out the need to control the inflammatory process at an early stage avoiding chronic inflammation and heart failure. The diversity of inflammation further addresses the need for a tailored characterization of inflammation enabling differentiation of inflammation and subsequent target-specific strategies. It is expected that the characterization of the systemic and/or cardiac immune profile will be part of precision medicine in the future of cardiology.

Unsere Produktempfehlungen

e.Med Interdisziplinär


Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

e.Med Innere Medizin


Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Allgemeinmedizin


Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Über diesen Artikel

Weitere Artikel der Ausgabe 4/2017

Current Heart Failure Reports 4/2017Zur Ausgabe

Biomarkers of Heart Failure (W.H.W. Tang and J.L. Grodin, Section Editors)

The Basic Metabolic Profile in Heart Failure—Marker and Modifier

Pathophysiology of Myocardial Failure (Inder Anand and Maria Patarroyo-Aponte, Section Editors)

SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys

Comorbidities of Heart Failure (C Angermann & F Edelmann, Section Editors)

Towards Holistic Heart Failure Management—How to Tackle the Iron Deficiency Epidemic?

Pharmacologic Therapy (W H W Tang, Section Editor)

Therapeutic Strategies Targeting Inherited Cardiomyopathies

Pathophysiology of Myocardial Failure (Inder Anand and Maria Patarroyo-Aponte, Section Editors)

Treatment of Hyperkalemia in Heart Failure

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.